INVASIVE ASPERGILLOSIS IN CHILDREN: UPDATE ON CURRENT GUIDELINES

Main Article Content

Athanasia Apsemidou *
Nikolaos Petridis
Timoleon-Achilleas Vyzantiadis
Athanasios Tragiannidis
(*) Corresponding Author:
Athanasia Apsemidou | sissyaps@gmail.com

Abstract

Invasive aspergillosis (IA) is an important cause of infectious morbidity and mortality in immunocompromised paediatric patients. Despite improvements in diagnosis, prevention and treatment, IA is still associated with high mortality rates. To address this issue, several international societies and organisations have proposed guidelines for the management of IA in the paediatric population. In this article, we review current recommendations of the Infectious Diseases Society of America, the European Conference on Infection in Leukaemia and the European Society of Clinical Microbiology and Infectious Diseases for the management and prevention of IA in children.


Downloads month by month

Downloads

Download data is not yet available.

Article Details

References

References
1. Tragiannidis A, Roilides E, Walsh TJ and Groll AH. Invasive aspergillosis in children with acquired immunodeficiencies. Clin Infect Dis. 2012; 54: 258-256
2. Zaoutis TE, Heydon K, Chu JH, Walsh TJ, Steinbach WJ. Epidemiology, outcomes, and costs of invasive aspergillosis in immunocompromised children in the United States, 2000. Pediatrics 2006; 117: 711-716.
3. Burgos A, Zaoutis TE, Dvorak CC, Hoffman JA, Knapp KM, Nania JJ, Prasad P, Steinbach WJ. Pediatric invasive aspergillosis: a multicenter retrospective analysis of 139 contemporary cases. Pediatrics 2008; 121: 1286-1294.
4. Walmsley S, Devi S, King S, Schneider R, Richardson S, Ford-Jones L. Invasive Aspergillus infections in a pediatric hospital: a ten-year review. Pediatr Infect Dis J 1993; 12: 673-682.
5. Abbasi S, Shenep JL, Hughes WT, Flynn PM. Aspergillosis in children with cancer: a 34-year experience. Clin Infect Dis 1999; 29:1210-1219.
6. Groll AH, Kurz M, Schneider W, Witt V, Schmidt H, Schneider M, Schwabe D. Five-year-survey of invasive aspergillosis in a paediatric cancer centre. Epidemiology, management and long-term survival. Mycoses. 1999; 42: 431–442.
7. Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358-366.
8. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG.. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 2010; 50: 1091-1100.
9. Steinbach WJ. Epidemiology of Invasive Fungal Infections in Neonates and Children. Clin Microbiol Infect. 2010 ;16: 1321-1327.
10. Segal BH. Aspergillosis. N Engl J Med 2009; 360: 1870–1884. doi: 10.1056/NEJMra0808853.
11. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med 1984; 100:345–51.
12. Thomas F. Patterson, George R. Thompson III, David W. Denning, Jay A. Fishman, Susan Hadley, Raoul Herbrecht, , Kontoyiannis DP, Marr KA, Morrison VA, Nguyen MH, Segal BH, Steinbach WJ, Stevens DA, Walsh TJ, Wingard JR, Young JA, Bennett JE. Guidelines for the Diagnosis and Management of Aspergillosis: 2016 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2016. 15; 63(4): e1-e60.
13. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo P. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11: 187-290.
14. Kerl K, Koch B, Fegeler W, Rossig C, Ehlert K, Groll AH. Catheter-associated aspergillosis of the chest wall following allogeneic hematopoietic stem cell transplantation. Transpl Infect Dis 2011; 13: 182-185.
15. Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987; 317: 1105-1108.
16. Lin SJ, Schranz J, Teutsch SM: Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001; 32: 358–366
17. Hovi L, Saarinen-Pihkala UM, Vettenranta K, Saxen H. Invasive fungal infections in pediatric bone marrow transplant recipients: single center experience of 10 years. Bone Marrow Transplant 2000; 26: 999-1004.
18. Benjamin DK Jr., Miller WC, Bayliff S, Martel L, Alexander KA, Martin PL. Infections diagnosed in the first year after pediatric stem cell transplantation. Pediatr Infect Dis J 2002; 21: 227-234.
19. Crassard N, Hadden H, Pondarré C, , Hadden R, Galambrun C, Piens MA, Pracros JP, Souillet G, Basset T, Berthier JC, Philippe N, Bertrand Y Invasive aspergillosis and allogeneic hematopoietic stem cell transplantation in children: a 15-year experience. Transpl Infect Dis 2008;10:177-183
20. Castagnola E, Faraci M, Moroni C, , R Bandettini, C Granata, S Caruso, F Bagnasco, I Caviglia, M Malgorzata, E Furfaro, A R Natalizia, V de Fazio, G Morreale, E Lanino, R Haupt, G Dini & C Viscoli. Invasive mycoses in children receiving hemopoietic SCT. Bone Marrow Transplant 2008;41 Suppl 2:S107-11.
21. Dotis J, Iosifidis E, Roilides E. Central nervous system aspergillosis in children: a systematic review of reported cases. Int J Infect Dis 2007; 11: 381–393
22. Andreas H Groll, Elio Castagnola, Simone Cesaro, Jean-Hugues Dalle, Dan Engelhard, William Hope, Emmanuel Roilides, Jan Styczynski, Adilia Warris, Thomas Lehrnbecher. Fourth European Conference on Infections in Leukaemia (ECIL-4): guidelines for diagnosis, prevention, and treatment of invasive fungal diseases in paediatric patients with cancer or allogeneic haemopoietic stem-cell transplantation. Lancet Oncol 2014; 15: 327–340
23. Ullmann AJ. Aguado JM. Arikan-Akdagli S, Denning D, Groll A, Lagrou K , C. Lass-Flör, R.E. Lewis, P. Muno, P.E. Verweij, A. Warris, F. Ader, M. Akova, M.C. Arendrup, R.A. Barnes, C. Beigelman-Aubry, S. Blot, E. Bouza, R.J.M. Brüggemann, D. Buchheidt, J. Cadranel, E. Castagnola, A. Chakrabarti, M. Cuenca-Estrella, G. Dimopoulos, J. Fortun, J.-P. Gangneux, J. Garbino, W.J. Heinz, R. Herbrecht, C.P. Heussel, C.C. Kibbler, N. Klimko, B.J. Kullberg, C. Lange, T. Lehrnbecher, J. Löffler, O. Lortholary, J. Maertens, O. Marchetti, J.F. Meis, L. Pagano, P. Ribaud, M. Richardson, E. Roilides, M. Ruhnke, M. Sanguinetti, D.C. Sheppard, J. Sinkó, A. Skiada, M.J.G.T. Vehreschild, C. Viscoli, O.A. Cornel. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection. 2018. https://doi.org/10.1016/j.cmi.2018.01.002.
24. Fraczek MG, Kirwan MB, Moore CB, Morris J, Denning DW, Richardson MD. Volume dependency for culture of fungi from respiratory secretions and increased sensitivity of aspergillus quantitative pcr. Mycoses. 2014; 57: 69-78.
25. Dornbusch HJ, Manzoni P, Roilides E, Walsh TJ, Groll AH. Invasive fungal infections in children. Pediatr Infect Dis J 2009; 28: 734–737.
26. Dornbusch HJ, Groll A, Walsh TJ. Diagnosis of invasive fungal infections in immunocompromised children. Clin Microbiol Infect 2010; 16: 1328–1334.
27. Roilides E. Early diagnosis of invasive aspergillosis in infants and children. Med Mycol 2006; 44: 199-205
28. Guarner J, Brandt ME. Histopathologic diagnosis of fungal infections in the 21st century. Clin Microbiol Rev 2011; 24:247–280
29. Vyzantiadis TA, Johnson EM, Kibbler CC. From the patient to the clinical mycology laboratory: how can we optimise microscopy and culture methods for mould identification? J Clin Pathol 2012; 65:475–483
30. Barton RC.Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction of outcome. Scientifica 2013; 2013:459405.
31. Lehrnbecher T, Phillips R, Alexander S, Alexander S, Ammann RA, Beauchemin M, Carlesse F, Groll AH, Haeusler GM, Santolaya M, Steinbach WJ, Castagnola E, Davis BL, Dupuis LL, Gaur AH, Tissing WJE, Zaoutis T, Phillips R, Sung L and the International Pediatric Fever and Neutropenia Guideline Panel. Guideline for the management of fever and neutropenia in children with cancer and/ or undergoing hematopoietic stem-cell transplantation. J Clin Oncol 2012; 30: 4427–4438.
32. Groll AH, Tragiannidis A. Recent advances in antifungal prevention and treatment. Semin Hematol 2009; 46: 212-229.
33. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: A meta-analysis. Clin Infect Dis. 2006; 42: 1417-1427.
34. Hovi L, Saxen H, Saarinen-Pihkala UM, Vettenranta K, Meri T, Richardson M. Prevention and monitoring of invasive fungal infections in pediatric patients with cancer and hematologic disorders. Pediatr Blood Cancer. 2007; 48: 28-34.
35. Steinbach WJ, Addison RM, McLaughlin L, Gerrald Q, Martin PL, Driscoll T, Bentsen C, Perfect JR, Alexander BD. Prospective aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J. 2007; 26: 558-564.
36. Hayden R, Pounds S, Knapp K, Petraitiene R, Schaufele RL, Sein T, Walsh TJ. Galactomannan antigenemia in pediatric oncology patients with invasive aspergillosis. Pediatr Infect Dis J. 2008; 27: 815-819.
37. Castagnola E, Furfaro E, Caviglia I, Licciardello M, Faraci M, Fioredda F, Tomà P, Bandettini R, Machetti M, Viscoli C. Performance of the galactomannan antigen detection test in the diagnosis of invasive aspergillosis in children with cancer or undergoing haemopoietic stem cell transplantation. Clin Microbiol Infect. 2010; 16: 1197-1203.
38. Fisher BT, Zaoutis TE, Park JR, Bleakley M, Englund JA, Kane C, Arceci RJ, Guinan E, Smith FO, Luan X, Marr KA. Galactomannan antigen testing for diagnosis of invasive aspergillosis in pediatric hematology patients. J Pediatric Infect Dis Soc. 2012; 1: 103-111.
39. Choi SH, Kang ES, Eo H, Yoo SY, Kim JH, Yoo KH, Sung KW, Koo HH, Kim YJ. Aspergillus galactomannan antigen assay and invasive aspergillosis in pediatric cancer patients and hematopoietic stem cell transplant recipients. Pediatr Blood Cancer. 2013; 60: 316-322.
40. Jha AK, Bansal D, Chakrabarti A, Shivaprakash MR, Trehan A, Marwaha RK. Serum galactomannan assay for the diagnosis of invasive aspergillosis in children with haematological malignancies. Mycoses. 2013; 56: 442-448.
41. Dinand V, Anjan M, Oberoi JK, , Khanna S, Yadav SP, Wattal C, Sachdeva A. Threshold of galactomannan antigenemia positivity for early diagnosis of invasive aspergillosis in neutropenic children. J Microbiol Immunol Infect. 2016; 49: 66-73.
42. Viscoli C, Machetti M, Cappellano P, B Bucci, P Bruzzi, MT Van Lint, A Bacigalupo. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913-916.
43. Aubry A, Porcher R, Bottero J, , Touratier S, Leblanc T, Brethon B, Rousselot P, Raffoux E, Menotti J, Derouin F, Ribaud P, Sulahian A. Occurrence and kinetics of false-positive Aspergillus galactomannan test results following treatment with beta-lactam antibiotics in patients with hematological disorders. J Clin Microbiol 2006; 44: 389-394.
44. Mennink-Kersten MA, Klont RR, Warris A, Op den Camp HJ, Verweij PE. Bifidobacterium lipoteichoic acid and false ELISA reactivity in Aspergillus antigen detection. Lancet 2004; 363: 325-327.
45. Mennink-Kersten MA, Verweij PE. Non-culture-based diagnostics for opportunistic fungi. Infect Dis Clin North Am 2006; 20: 711-727.
46. Duarte RF, Sanchez-Ortega I, Cuesta I, Arnan M, Patiño B, Fernández de Sevilla A, Gudiol C, Ayats J, Cuenca-Estrella M. Serum galactomannan-based early detection of invasive aspergillosis in hematology patients receiving effective antimold prophylaxis. Clin Infect Dis. 2014; 59: 1696-1702.
47. Teering S, Verreth A, Peeters A, Van Regenmortel N, De Laet I, Schoonheydt K, Dits H, Van De Vyvere M, Libeer C, Meersseman W, Malbrain ML. Prognostic value of serum galactomannan in mixed icu patients: A retrospective observational study. Anaesthesiol Intensive Ther. 2014; 46: 145-154
48. Challier S, Boyer S, Abachin E, Berche P. Development of a serum-based Taqman real-time PCR assay for diagnosis of invasive aspergillosis. J Clin Microbiol 2004; 42: 844-846.
49. El-Mahallawy HA, Shaker HH, Ali Helmy H, Mostafa T, Razak Abo-Sedah A. Evaluation of pan-fungal PCR assay and Aspergillus antigen detection in the diagnosis of invasive fungal infections in high risk paediatric cancer patients. Med Mycol 2006; 44: 733-739.
50. Steinbach WJ, Addison RM, McLaughlin L, Gerrald Q, Martin PL, Driscoll T, Bentsen C, Perfect JR, Alexander BD. Prospective Aspergillus galactomannan antigen testing in pediatric hematopoietic stem cell transplant recipients. Pediatr Infect Dis J 2007; 26: 558-564.
51. Pfeiffer CD, Fine JP, Safdar N. Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis. Clin Infect Dis 2006; 42: 1417-1427.
52. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: A prospective validation. Blood. 2001; 97: 1604-1610.
53. Hoenigl M, Seeber K, Koidl C, Buzina W, Wölfler A, Duettmann W, Wagner J, Strenger V, Krause R. Sensitivity of galactomannan enzyme immunoassay for diagnosing breakthrough invasive aspergillosis under antifungal prophylaxis and empirical therapy. Mycoses. 2013; 56: 471-476.
54. Marr KA, Laverdiere M, Gugel A, Leisenring W. Antifungal therapy decreases sensitivity of the aspergillus galactomannan enzyme immunoassay. Clin Infect Dis. 2005; 40: 1762-1769.
55. Cordonnier C, Botterel F, Ben Amor R, Pautas C, Maury S, Kuentz M, Hicheri Y, Bastuji-Garin S, Bretagne S. Correlation between galactomannan antigen levels in serum and neutrophil counts in haematological patients with invasive aspergillosis. Clin Microbiol Infect. 2009; 15: 81-86.
56. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, Wilmer A, Verhaegen J, Boogaerts M, Van Eldere J . Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: A prospective feasibility study. Clin Infect Dis. 2005; 41: 1242-1250.
57. Guinea J, Jensen J, Peláez T, Gijón P, Alonso R, Rivera M, Muñoz P, Bouza E. Value of a single galactomannan determination (platelia) for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation of aspergillus spp. Med Mycol. 2008; 46: 575-579.
58. Meersseman W, Lagrou K, Maertens J, Wilmer A, Hermans G, Vanderschueren S, Spriet I, Verbeken E, Van Wijngaerden E. Galactomannan in bronchoalveolar lavage fluid: A tool for diagnosing aspergillosis in intensive care unit patients. Am J Respir Crit Care Med. 2008; 177: 27-34.
59. Husain S, Kwak EJ, Obman A, Wagener MM, Kusne S, Stout JE, McCurry KR, Singh N. Prospective assessment of platelia aspergillus galactomannan antigen for the diagnosis of invasive aspergillosis in lung transplant recipients. Am J Transplant. 2004; 4: 796-802.
60. Tabarsi P, Soraghi A, Marjani M, Zandian P, Baghaei P, Najafizadeh K, Droudinia A, Sarrafzadeh SA, Javanmard P, Mansouri D. Comparison of serum and bronchoalveolar lavage galactomannan in diagnosing invasive aspergillosis in solid-organ transplant recipients. Exp Clin Transplant. 2012; 10: 278-281.
61. Guigue N, Menotti J, Ribaud P. False positive galactomannan test after ice-pop ingestion. N Engl J Med. 2013; 369: 97-98.
62. Petraitiene R, Petraitis V, Witt JR, 3rd, Durkin MM, Bacher JD, Wheat LJ, Walsh TJ. Galactomannan antigenemia after infusion of gluconate-containing plasma-lyte. J Clin Microbiol. 2011; 49: 4330-4332.
63. Martin-Rabadan P, Gijon P, Alonso Fernandez R, Ballesteros M, Anguita J, Bouza E. False-positive aspergillus antigenemia due to blood product conditioning fluids. Clin Infect Dis. 2012; 55: e22-27.
64. Mikulska M, Furfaro E, Del Bono V, Raiola AM, Ratto S, Bacigalupo A, Viscoli C. Piperacillin/tazobactam (tazocintm) seems to be no longer responsible for false-positive results of the galactomannan assay. J Antimicrob Chemother. 2012; 67: 1746-1748.
65. Vergidis P, Walker RC, Kaul DR, Kauffman CA, Freifeld AG, Slagle DC, Kressel AB, Wheat LJ. False-positive aspergillus galactomannan assay in solid organ transplant recipients with histoplasmosis. Transpl Infect Dis. 2012; 14: 213-217.
66. Huang YT, Hung CC, Liao CH, Sun HY, Chang SC, Chen YC. Detection of circulating galactomannan in serum samples for diagnosis of penicillium marneffei infection and cryptococcosis among patients infected with human immunodeficiency virus. J Clin Microbiol. 2007; 45: 2858-2862.
67. Nucci M, Carlesse F, Cappellano P, Varon AG1, Seber A2, Garnica M1, Nouér SA1, Colombo AL. Earlier diagnosis of invasive fusariosis with aspergillus serum galactomannan testing. PLoS One. 2014; 9: e87784.
68. King ST, Stover KR. Considering confounders of the galactomannan index: The role of piperacillin-tazobactam. Clin Infect Dis. 2014; 58: 751-752.
69. Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012; 50: 2330-2336.
70. Roilides E, Pavlidou E, Papadopoulos F, Panteliadis C, Farmaki E, Tamiolaki M, Sotiriou J. Cerebral aspergillosis in an infant with corticosteroid-resistant nephrotic syndrome. Pediatr Nephrol 2003; 18: 450–53.
71. Viscoli C, Machetti M, Gazzola P, De Maria A, Paola D, Van Lint MT, Gualandi F, Truini M , and Bacigalupo A. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant recipients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496-1499.
72. Smith PB, Benjamin DK, Jr., Alexander BD, Johnson MD, Finkelman MA, Steinbach WJ. Quantification of 1, 3-beta-d-glucan levels in children: Preliminary data for diagnostic use of the beta-glucan assay in a pediatric setting. Clin Vaccine Immunol. 2007; 14: 924-925.
73. Zhao L, Tang JY, Wang Y, Zhou YF, Chen J, Li BR, Xue HL. [value of plasma beta-glucan in early diagnosis of invasive fungal infection in children]. Zhongguo Dang Dai Er Ke Za Zhi. 2009; 11: 905-908.
74. Mularoni A, Furfaro E, Faraci M, Franceschi A, Mezzano P, Bandettini R, Viscoli C, Castagnola E. High levels of beta-d-glucan in immunocompromised children with proven invasive fungal disease. Clin Vaccine Immunol. 2010; 17: 882-883.
75. Badiee P, Alborzi A, Karimi M, Pourabbas B, Haddadi P, Mardaneh J, Moieni M. Diagnostic potential of nested pcr, galactomannan eia, and beta-d-glucan for invasive aspergillosis in pediatric patients. J Infect Dev Ctries. 2012; 6: 352-357.
76. Koltze A, Rath P, Schoning S, Steinmann J, Wichelhaus TA, Bader P, Bochennek K, Lehrnbecher T. Beta-d-glucan screening for detection of invasive fungal disease in children undergoing allogeneic hematopoietic stem cell transplantation. J Clin Microbiol. 2015; 53: 2605-2610.
77. Ostrosky-Zeichner L, Alexander BD, Kett DH, , Vazquez J, Pappas PG, Saeki F, Ketchum PA, Wingard J, Schiff R, Tamura H, Finkelman MA, Rex JH. Multicenter clinical evaluation of the (1-->3) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin Infect Dis 2005; 41:654–659.
78. Odabasi Z, Mattiuzzi G, Estey E, Kantarjian H, Saeki F, Ridge RJ, Ketchum PA, Finkelman MA, Rex JH, Ostrosky-Zeichner L. Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome. Clin Infect Dis 2004; 39:199–205
79. De Pauw B, Walsh TJ, Donnelly JP, David A. Stevens, John E. Edwards, Thierry Calandra, Peter G. Pappas, Johan Maertens, Olivier Lortholary, Carol A. Kauffman, David W. Denning, Thomas F. Patterson, Georg Maschmeyer, Jacques Bille, William E. Dismukes, Raoul Herbrecht, William W. Hope, Christopher C. Kibbler, Bart Jan Kullberg, Kieren A. Marr, Patricia Muñoz, Frank C. Odds, John R. Perfect, Angela Restrepo, Markus Ruhnke, Brahm H. Segal, Jack D. Sobel, Tania C. Sorrell, Claudio Viscoli, John R. Wingard, Theoklis Zaoutis, and John E. Bennett.; European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group; National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis 2008; 46: 1813–1821
80. Hummel M, Spiess B, Roder J, von Komorowski G, Dürken M, Kentouche K, Laws HJ, Mörz H, Hehlmann R, Buchheidt D. Detection of Aspergillus DNA by a nested PCR assay is able to improve the diagnosis of invasive aspergillosis in paediatric patients. J Med Microbiol 2009; 58: 1291-1297.
81. Taccone A, Occhi M, Garaventa A, Manfredini L, Viscoli C. Ct of invasive pulmonary aspergillosis in children with cancer. Pediatr Radiol. 1993; 23: 177-180.
82. Archibald S, Park J, Geyer JR, Hawkins DS. Computed tomography in the evaluation of febrile neutropenic pediatric oncology patients. Pediatr Infect Dis J. 2001; 20: 5-10.
83. Neely M, Margol A, Fu X, van Guilder M, Bayard D, Schumitzky A, Orbach R, Liu S, Louie S, Hope W. Achieving target voriconazole concentrations more accurately in children and adolescents. Antimicrob Agents Chemother. 2015; 59: 3090-3097.
84. Friberg LE, Ravva P, Karlsson MO, Liu P. Integrated population pharmacokinetic analysis of voriconazole in children, adolescents and adults. Antimicrob Agents Chemother. 2012; 56: 3032-3042.
85. Gavalda J, Meije Y, Fortun J, Roilides E, Saliba F, Lortholary O, Muñoz P, Grossi P, Cuenca-Estrella M; ESCMID Study Group for Infections in Compromised Hosts. Invasive fungal infections in solid organ transplant recipients. Clin Microbiol Infect. 2014; 20 Suppl 7: 27-48.
86. Husain S, Zaldonis D, Kusne S, Kwak EJ, Paterson DL, McCurry KR. Variation in antifungal prophylaxis strategies in lung transplantation. Transpl Infect Dis. 2006; 8: 213-218.
87. Hope WW, Castagnola E, Groll AH, Roilides E, Akova M, Arendrup MC, Arikan-Akdagli S, Bassetti M, Bille J, Cornely OA, Cuenca-Estrella M, Donnelly JP, Garbino J, Herbrecht R, Jensen HE, Kullberg BJ, Lass-Flörl C, Lortholary O, Meersseman W, Petrikkos G, Richardson MD, Verweij PE, Viscoli C, Ullmann AJ; ESCMID Fungal Infection Study Group. ESCMID* guideline for the diagnosis and management of candida diseases 2012: prevention and management of invasive infections in neonates and children caused by Candida spp. Clin Microbiol Infect 2012; 18: 38–52.
88. van Burik JA, Ratanatharathorn V, Stepan DE, , Miller CB, Lipton JH, Vesole DH, Bunin N, Wall DA, Hiemenz JW, Satoi Y, Lee JM, Walsh TJ; National Institute of Allergy and Infectious Diseases Mycoses Study Group. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407–16. 48
89. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network. Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 2010; 116: 5111–5118.
90. Dvorak CC, Fisher BT, Sung L, Steinbach WJ, Nieder M, Alexander S, Zaoutis TE. Antifungal prophylaxis in pediatric hematology/oncology: new choices and new data. Pediatr Blood Cancer 2012; 59: 21–26.
91. Tragiannidis A, Dokos C, Lehrnbecher T, Groll AH. Antifungal chemoprophylaxis in children and adolescents with haematological malignancies and following allogeneic haematopoietic stem cell transplantation: review of the literature and options for clinical practice. Drugs 2012; 72: 685–704.
92. Cornely OA, Maertens J, Winston DJ, Perfect J, Ullmann AJ, Walsh TJ, Helfgott D, Holowiecki J, Stockelberg D, Goh YT, Petrini M, Hardalo C, Suresh R, Angulo-Gonzalez D. Posaconazole vs. Fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med. 2007; 356: 348-359.
93. Ullmann AJ, Lipton JH, Vesole DH, Chandrasekar P, Langston A, Tarantolo SR, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, Patino H, Durrant S. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med. 2007; 356: 335-347.
94. Ananda-Rajah MR, Grigg A, Downey MT, A Bajel, T Spelman, A Cheng, K T. Thursky, J Vincent,and MA Slavin. Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year period. Haematologica. 2012; 97: 459-463.
95. Ananda-Rajah MR, Grigg A, Slavin MA. Making sense of posaconazole therapeutic drug monitoring: A practical approach. Curr Opin Infect Dis. 2012; 25: 605-611.
96. Cornely OA, Ullmann AJ. Lack of evidence for exposure-response relationship in the use of posaconazole as prophylaxis against invasive fungal infections. Clin Pharmacol Ther. 2011; 89: 351-352.
97. Krishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft-versus-host disease. Pharmacotherapy. 2007; 27: 1627-1636.
98. Welzen ME, Bruggemann RJ, Van Den Berg JM, Voogt HW, Gilissen JH, Pajkrt D, Klein N, Burger DM, Warris A. A twice daily posaconazole dosing algorithm for children with chronic granulomatous disease. Pediatr Infect Dis J. 2011; 30: 794-797.
99. Doring M, Muller C, Johann PD, Erbacher A, Kimmig A, Schwarze CP, Lang P, Handgretinger R, Müller I. Analysis of posaconazole as oral antifungal prophylaxis in pediatric patients under 12 years of age following allogeneic stem cell transplantation. BMC Infect Dis. 2012; 12: 263.
100. Lehrnbecher T, Attarbaschi A, Duerken M, Garbino J, Gruhn B, Kontny U, Lüer S, Phillips R, Scholz J, Wagner HJ, Wiesel T, Groll AH. Posaconazole salvage treatment in paediatric patients: A multicentre survey. Eur J Clin Microbiol Infect Dis. 2010; 29: 1043-1045.
101. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G; IMPROVIT Study Group. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Br J Haematol. 2011; 155: 318-327.
102. Mattiuzzi GN, Cortes J, Alvarado G, Verstovsek S, Koller C, Pierce S, Blamble D, Faderl S, Xiao L, Hernandez M, Kantarjian H. Efficacy and safety of intravenous voriconazole and intravenous itraconazole for antifungal prophylaxis in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome. Support Care Cancer. 2011; 19: 19-26.
103. Barreto JN, Beach CL, Wolf RC, Merten JA, Tosh PK, Wilson JW, Hogan WJ, Litzow MR. The incidence of invasive fungal infections in neutropenic patients with acute leukemia and myelodysplastic syndromes receiving primary antifungal prophylaxis with voriconazole. Am J Hematol. 2013; 88: 283-288.
104. Walsh TJ, Karlsson MO, Driscoll T, Arguedas AG, Adamson P, Saez-Llorens X, Vora AJ, Arrieta AC, Blumer J, Lutsar I, Milligan P, Wood N. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother. 2004; 48: 2166-2172.
105. Karlsson MO, Lutsar I, Milligan PA. Population pharmacokinetic analysis of voriconazole plasma concentration data from pediatric studies. Antimicrob Agents Chemother. 2009; 53: 935-944.
106. Driscoll TA, Frangoul H, Nemecek ER, Murphey DK, Yu LC, Blumer J, Krance RA, Baruch A, Liu P. Comparison of pharmacokinetics and safety of voriconazole intravenous-to-oral switch in immunocompromised adolescents and healthy adults. Antimicrob Agents Chemother. 2011; 55: 5780-5789.
107. Soler-Palacin P, Frick MA, Martin-Nalda A, Lanaspa M, Pou L, Roselló E, de Heredia CD, Figueras C. Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: A prospective study. J Antimicrob Chemother. 2012; 67: 700-706.
108. Pieper S, Kolve H, Gumbinger HG, Goletz G, Wurthwein G, Groll AH. Monitoring of voriconazole plasma concentrations in immunocompromised paediatric patients. J Antimicrob Chemother. 2012; 67: 2717-2724.
109. Molina JR, Serrano J, Sanchez-Garcia J, Rodríguez-Villa A, Gómez P, Tallón D, Martín V, Rodríguez G, Rojas R, Martín C, Martínez F, Alvarez MA, Torres A. Voriconazole as primary antifungal prophylaxis in children undergoing allo-sct. Bone Marrow Transplant. 2012; 47: 562-567.
110. Troke PF, Hockey HP, Hope WW. Observational study of the clinical efficacy of voriconazole and its relationship to plasma concentrations in patients. Antimicrob Agents Chemother. 2011; 55: 4782-4788.
111. Park WB, Kim N-H, Kim K-H, Lee SH, Nam WS, Yoon SH, Song KH, Choe PG, Kim NJ, Jang IJ, Oh MD, Yu KS. The effect of therapeutic drug monitoring on safety and efficacy of voriconazole in invasive fungal infections: A randomized controlled trial. Clin Infect Dis. 2012; 55: 1080-1087.
112. Winston DJ, Maziarz RT, Chandrasekar PH, , Lazarus HM, Goldman M, Blumer JL, Leitz GJ, Territo MC. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long-term antifungal prophylaxis in allogeneic hematopoietic stem-cell transplant recipients. A multicenter, randomized trial. Ann Intern Med. 2003; 138: 705-713.
113. Marr KA, Crippa F, Leisenring W, Hoyle M, Boeckh M, Balajee SA, Nichols WG, Musher B, Corey L. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood. 2004; 103: 1527-1533.
114. Marr KA, Leisenring W, Crippa F, Slattery JT, Corey L, Boeckh M, McDonald GB. Cyclophosphamide metabolism is affected by azole antifungals. Blood. 2004; 103: 1557-1559.
115. Menichetti F, Del Favero A, Martino P, , Bucaneve G, Micozzi A, Girmenia C, Barbabietola G, Pagańo L, Leoni P, Specchia G, Caiozzo A, Raimondi R, Mandelli F. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: A randomized, placebo-controlled, double-blind, multicenter trial. Gimema infection program. Gruppo italiano malattie ematologiche dell' adulto. Clin Infect Dis. 1999; 28: 250-255.
116. Prentice HG, Caillot D, Dupont B, Menichetti F, Schuler U. Oral and intravenous itraconazole for systemic fungal infections in neutropenic haematological patients: Meeting report. London, united kingdom, 20 june 1998. Acta Haematol. 1999; 101: 56-62.
117. Harousseau JL, Dekker AW, Stamatoullas-Bastard A, Fassas A, Linkesch W, Gouveia J, De Bock R, Rovira M, Seifert WF, Joosen H, Peeters M, De Beule K. Itraconazole oral solution for primary prophylaxis of fungal infections in patients with hematological malignancy and profound neutropenia: A randomized, double-blind, double-placebo, multicenter trial comparing itraconazole and amphotericin b. Antimicrob Agents Chemother. 2000; 44: 1887-1893.
118. Gallin JI, Alling DW, Malech HL, Wesley R, Koziol D, Marciano B, Eisenstein EM, Turner ML, DeCarlo ES, Starling JM, Holland SM. Itraconazole to prevent fungal infections in chronic granulomatous disease. N Engl J Med. 2003; 348: 2416-2422.
119. de Repentigny L, Ratelle J, Leclerc JM, Cornu G, Sokal EM, Jacqmin P, De Beule K.. Repeated-dose pharmacokinetics of an oral solution of itraconazole in infants and children. Antimicrob Agents Chemother. 1998; 42: 404-408.
120. Groll AH, Wood L, Roden M, Mickiene D, Chiou CC, Townley E, Dad L, Piscitelli SC, Walsh TJ. Safety, pharmacokinetics, and pharmacodynamics of cyclodextrin itraconazole in pediatric patients with oropharyngeal candidiasis. Antimicrob Agents Chemother. 2002; 46: 2554-2563.
121. Foot AB, Veys PA, Gibson BE. Itraconazole oral solution as antifungal prophylaxis in children undergoing stem cell transplantation or intensive chemotherapy for haematological disorders. Bone Marrow Transplant. 1999; 24: 1089-1093.
122. Simon A, Besuden M, Vezmar S, Hasan C, Lampe D, Kreutzberg S, Glasmacher A, Bode U, Fleischhack G . Itraconazole prophylaxis in pediatric cancer patients receiving conventional chemotherapy or autologous stem cell transplants. Support Care Cancer. 2007; 15: 213-220.
123. Glasmacher A, Hahn C, Molitor E, Marklein G, Sauerbruch T, Schmidt-Wolf I. Itraconazole trough concentrations in antifungal prophylaxis with six different dosing regimens using hydroxypropyl-ß-cyclodextrin oral solution or coated-pellet capsules. Mycoses. 1999; 42: 591-600.
124. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Sparrelid E, Tydén G. Prophylactic use of liposomal amphotericin b (ambisome) against fungal infections: A randomized trial in bone marrow transplant recipients. Transplant Proc. 1993; 25: 1495-1497.
125. Tollemar J, Ringden O, Andersson S, Sundberg B, Ljungman P, Tyden G. Randomized double-blind study of liposomal amphotericin b (ambisome) prophylaxis of invasive fungal infections in bone marrow transplant recipients. Bone Marrow Transplant. 1993; 12: 577-582.
126. Kelsey SM, Goldman JM, McCann S, Newland AC, Scarffe JH, Oppenheim BA, Mufti GJ.. Liposomal amphotericin (ambisome) in the prophylaxis of fungal infections in neutropenic patients: A randomised, double-blind, placebo-controlled study. Bone Marrow Transplant. 1999; 23: 163-168.
127. Penack O, Schwartz S, Martus P, Reinwald M, Schmidt-Hieber M, Thiel E, Blau IW. Low-dose liposomal amphotericin b in the prevention of invasive fungal infections in patients with prolonged neutropenia: Results from a randomized, single-center trial. Ann Oncol. 2006; 17: 1306-1312.
128. Hong Y, Shaw PJ, Nath CE, , Yadav SP, Stephen KR, Earl JW, McLachlan AJ.. Population pharmacokinetics of liposomal amphotericin b in pediatric patients with malignant diseases. Antimicrob Agents Chemother. 2006; 50: 935-942.
129. Ringden O, Meunier F, Tollemar J, Ricci P, Tura S, Kuse E, Viviani MA, Gorin NC, Klastersky J, Fenaux P. Efficacy of amphotericin b encapsulated in liposomes (ambisome) in the treatment of invasive fungal infections in immunocompromised patients. J Antimicrob Chemother. 1991; 28 Suppl B: 73-82.
130. Kolve H, Ahlke E, Fegeler W, Ritter J, Jurgens H, Groll AH. Safety, tolerance and outcome of treatment with liposomal amphotericin b in paediatric patients with cancer or undergoing haematopoietic stem cell transplantation. J Antimicrob Chemother. 2009; 64: 383-387.
131. Huang X, Chen H, Han M, Zou P, Wu D, Lai Y, Huang H, Chen X, Liu T, Zhu H, Wang J, Hu J . Multicenter, randomized, open-label study comparing the efficacy and safety of micafungin versus itraconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplant. Biol Blood Marrow Transplant. 2012; 18: 1509-1516.
132. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DN, Walsh TJ. Safety, tolerability, and pharmacokinetics of micafungin (fk463) in febrile neutropenic pediatric patients. Antimicrob Agents Chemother. 2005; 49: 3317-3324.
133. Hope WW, Seibel NL, Schwartz CL, , Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ, Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population pharmacokinetics of micafungin in pediatric patients and implications for antifungal dosing. Antimicrob Agents Chemother. 2007; 51: 3714-3719.
134. Arrieta AC, Maddison P, Groll AH. Safety of micafungin in pediatric clinical trials. Pediatr Infect Dis J. 2011; 30: e97-e102.
135. Mehta PA, Vinks AA, Filipovich A, , Bleesing J, Jodele S, Jordan MB, Marsh R, Tarin R, Edwards S, Fearing D, Lawrence J, Davies SM. Alternate-day micafungin antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: A pharmacokinetic study. Biol Blood Marrow Transplant. 2010; 16: 1458-1462.
136. Beaute J, Obenga G, Le Mignot L, Mahlaoui N, Bougnoux ME, Mouy R, Gougerot-Pocidalo MA, Barlogis V, Suarez F, Lanternier F, Hermine O, Lecuit M, Blanche S, Fischer A, Lortholary O; French PID Study Group CEREDIH . Epidemiology and outcome of invasive fungal diseases in patients with chronic granulomatous disease: A multicenter study in france. Pediatr Infect Dis J. 2011; 30: 57-62.
137. Mouy R, Veber F, Blanche S, Donadieu J, Brauner R, Levron JC, Griscelli C, Fischer A.. Long-term itraconazole prophylaxis against aspergillus infections in thirty-two patients with chronic granulomatous disease. J Pediatr. 1994; 125: 998-1003.
138. Lestner JM, Smith PB, Cohen-Wolkowiez M, Benjamin DK Jr, Hope WW. Antifungal agents and therapy for infants and children with invasive fungal infections: a pharmacological perspective. Br J Clin Pharmacol 2013; 75: 1381–95. 5
139. Herbrecht R, Flückiger U, Gachot B, Ribaud P, Tiebaut A, Cordonnier C. Treatment of invasive candida and invasive aspergillus infections in adult haematological patients. Eur J Cancer 2007; 5:49–59.
140. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flückiger U, Frêre P, Gachot B, Heinz WJ, Lass-Flörl C, Ribaud P, Thiebaut A, Cordonnier C; Third European Conference on Infections in Leukemia. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: summary of the ECIL 3—2009 update. Bone Marrow Transplant 2011; 46: 709–18.
141. Jang SH, Colangelo PM, Gobburu JV. Exposure-response of posaconazole used for prophylaxis against invasive fungal infections: evaluating the need to adjust doses based on drug concentrations in plasma. Clin Pharmacol Ther 2010; 88: 115–119.
142. Groll AH, Tragiannidis A. Update on antifungal agents for paediatric patients. Clin Microbiol Infect 2010; 16: 1343–53
143. Sung L, Phillips R, Lehrnbecher T. Time for paediatric febrile neutropenia guidelines—children are not little adults. Eur J Cancer 2011; 47: 811–813
144. Allinson K, Kolve H, Gumbinger HG, Vormoor HJ, Ehlert K, Groll AH. Secondary antifungal prophylaxis in paediatric allogeneic haematopoietic stem cell recipients. J Antimicrob Chemother 2008; 61: 734–742.
145. Cordonnier C, Rovira M, Maertens J, Olavarria E, Faucher C, Bilger K, Pigneux A, Cornely OA, Ullmann AJ, Bofarull RM, de la Cámara R, Weisser M, Liakopoulou E, Abecasis M, Heussel CP, Pineau M, Ljungman P, Einsele H; Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI) study group; Infectious Diseases Working Party, European Group for Blood and Marrow Transplantation. Voriconazole for secondary prophylaxis of invasive fungal infections in allogeneic stem cell transplant recipients: results of the VOSIFI study. Haematologica 2010; 95: 1762–1768.
146. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, Warnock DW. Trends in mortality due to invasive mycotic diseases in the United States, 1980–1997. Clin Infect Dis. 2001; 33: 641–647.
147. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999; 29: 239–244.
148. Sung L, Lange BJ, Gerbing RB, Alonzo TA, Feusner J. Microbiologically documented infections and infection-related mortality in children with acute myeloid leukemia. Blood. 2007;110:3532–3539
149. Walsh TJ, Driscoll T, Milligan PA, Wood ND, Schlamm H, Groll AH, Jafri H, Arrieta AC, Klein NJ, Lutsar I. Pharmacokinetics, safety, and tolerability of voriconazole in immunocompromised children. Antimicrob Agents Chemother 2010; 54:4116–4123.
150. Walsh TJ, Adamson PC, Seibel NL, , Flynn PM, Neely MN, Schwartz C, Shad A, Kaplan SL, Roden MM, Stone JA, Miller A, Bradshaw SK, Li SX, Sable CA, Kartsonis NA. Pharmacokinetics, safety, and tolerability of caspofungin in children and adolescents. Antimicrob Agents Chemother 2005; 49:4536–4545.
151. Benjamin DKJ, Driscoll T, Seibel NL, Gonzalez CE, Roden MM, Kilaru R, Clark K, Dowell JA, Schranz J, Walsh TJ. Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections. Antimicrob Agents Chemother 2006; 50:632–638.
152. Caillot D, Thiébaut A, Herbrecht R, , de Botton S, Pigneux A, Bernard F, Larché J, Monchecourt F, Alfandari S, Mahi L. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: a randomized pilot study (Combistrat trial). Cancer 2007; 110: 2740–2746.
153. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis 2004; 39: 797–802.
154. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E, Haas A, Ruhnke M, Lode H. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34: 563-571.
155. Fortun J, Martin-Davila P, Sanchez MA, Pintado V, Alvarez ME, Sánchez-Sousa A, Moreno S. Voriconazole in the treatment of invasive mold infections in transplant recipients. Eur J Clin Microbiol Infect Dis. 2003; 22: 408-413.
156. Wieland T, Liebold A, Jagiello M, Retzl G, Birnbaum DE. Superiority of voriconazole over amphotericin b in the treatment of invasive aspergillosis after heart transplantation. J Heart Lung Transplant. 2005; 24: 102-104.
157. Veroux M, Corona D, Gagliano M, Sorbello M, Macarone M, Cutuli M, Giuffrida G, Morello G, Paratore A, Veroux P. Voriconazole in the treatment of invasive aspergillosis in kidney transplant recipients. Transplant Proc. 2007; 39: 1838-1840.
158. Doby EH, Benjamin DK, Jr., Blaschke AJ, Ward RM, Pavia AT, Martin PL, Driscoll TA, Cohen-Wolkowiez M, Moran C.Therapeutic monitoring of voriconazole in children less than three years of age: A case report and summary of voriconazole concentrations for ten children. Pediatr Infect Dis J. 2012; 31: 632-635.
159. Bartelink IH, Wolfs T, Jonker M, de Waal M, Egberts TC, Ververs TT, Boelens JJ, Bierings M. Highly variable plasma concentrations of voriconazole in pediatric hematopoietic stem cell transplantation patients. Antimicrob Agents Chemother. 2013; 57: 235-240.
160. Kotwani RN, Gokhale PC, Bodhe PV, Kirodian BG, Kshirsagar NA, Pandya SK. A comparative study of plasma concentrations of liposomal amphotericin b (l-amp-lrc-1) in adults, children and neonates. Int J Pharm. 2002; 238: 11-15.
161. Bochennek K, Tramsen L, Schedler N, Becker M, Klingebiel T, Groll AH, Lehrnbecher T. Liposomal amphotericin b twice weekly as antifungal prophylaxis in paediatric haematological malignancy patients. Clin Microbiol Infect. 2011; 17: 1868-1874.
162. Groll AH, Silling G, Young C, , Schwerdtfeger R, Ostermann H, Heinz WJ, Gerss J, Kolve H, Lanvers-Kaminsky C, Vieira Pinheiro JP, Gammelin S, Cornely OA, Wuerthwein G. Randomized comparison of safety and pharmacokinetics of caspofungin, liposomal amphotericin b, and the combination of both in allogeneic hematopoietic stem cell recipients. Antimicrob Agents Chemother. 2010; 54: 4143-4149.
163. K, Tsukimoto I, Tsunematsu Y, Honda M, Iwai N, Maniwa T, Haigo H, Suzuki K, Mori T. . Evaluation of the safety and efficacy of liposomal amphotericin b (l-amb) in children. J Infect Chemother. 2012; 18: 456-465.
164. Herbrecht R, Maertens J, Baila L, Aoun M, Heinz W, Martino R, Schwartz S, Ullmann AJ, Meert L, Paesmans M, Marchetti O, Akan H, Ameye L, Shivaprakash M, Viscoli C. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: An european organisation for research and treatment of cancer study. Bone Marrow Transplant. 2010; 45: 1227-1233.
165. Viscoli C, Herbrecht R, Akan H, Baila L, Sonet A, Gallamini A, Giagounidis A, Marchetti O, Martino R, Meert L, Paesmans M, Ameye L, Shivaprakash M, Ullmann AJ, Maertens J; Infectious Disease Group of the EORTC. An eortc phase ii study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009; 64: 1274-1281.
166. Cornely OA, Vehreschild JJ, Vehreschild MJ, Würthwein G, Arenz D, Schwartz S, Heussel CP, Silling G, Mahne M, Franklin J, Harnischmacher U, Wilkens A, Farowski F, Karthaus M, Lehrnbecher T, Ullmann AJ, Hallek M, Groll AH. Phase ii dose escalation study of caspofungin for invasive aspergillosis. Antimicrob Agents Chemother. 2011; 55: 5798-5803.
167. Groetzner J, Kaczmarek I, Wittwer T, Strauch J, Meiser B, Wahlers T, Daebritz S, Reichart B. Caspofungin as first-line therapy for the treatment of invasive aspergillosis after thoracic organ transplantation. J Heart Lung Transplant. 2008; 27: 1-6.
168. Winkler M, Pratschke J, Schulz U, Zheng S, Zhang M, Li W, Lu M, Sgarabotto D, Sganga G, Kaskel P, Chandwani S, Ma L, Petrovic J, Shivaprakash M .Caspofungin for post solid organ transplant invasive fungal disease: Results of a retrospective observational study. Transpl Infect Dis. 2010; 12: 230-237.
169. Neely M, Jafri HS, Seibel N, Knapp K, Adamson PC, Bradshaw SK, Strohmaier KM, Sun P, Bi S, Dockendorf MF, Stone JA, Kartsonis NA. Pharmacokinetics and safety of caspofungin in older infants and toddlers. Antimicrob Agents Chemother. 2009; 53: 1450-1456.
170. Cesaro S, Giacchino M, Locatelli F, , Spiller M, Buldini B, Castellini C, Caselli D, Giraldi E, Tucci F, Tridello G, Rossi MR, Castagnola E. Safety and efficacy of a caspofungin-based combination therapy for treatment of proven or probable aspergillosis in pediatric hematological patients. BMC Infect Dis. 2007; 7: 28.
171. Zaoutis T, Lehrnbecher T, Groll AH, Steinbach WJ, Jafri HS, Maertens J, Ngai AL, Chow JW, Taylor AF, Strohmaier KM, Bourque M, Bradshaw SK, Petrecz M, Kartsonis NA. Safety experience with caspofungin in pediatric patients. Pediatr Infect Dis J. 2009; 28: 1132-1135.
172. Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W, Steinbach WJ, Bradley J, Lieberman JM, Hsiao CC, Seibel N, Laws HJ, Gamba M, Petrecz M, Taylor AF, Strohmaier KM, Chow JW, Kartsonis NA, Ngai AL. A prospective, multicenter study of caspofungin for the treatment of documented candida or aspergillus infections in pediatric patients. Pediatrics. 2009; 123: 877-884.
173. Ngai AL, Bourque MR, Lupinacci RJ, Strohmaier KM, Kartsonis NA. Overview of safety experience with caspofungin in clinical trials conducted over the first 15 years: A brief report. Int J Antimicrob Agents. 2011; 38: 540-544.
174. Marr KAS, Rottinghaus H, Jagannatha S, H Jagannatha, E J. Bow, JR. Wingard, P Pappas, RHerbrecht, TJ. Walsh, J Maertens and the Mycoses Study Group. A randomised, double-blind study of combination antifungal therapy with voriconazole and anidalafungin versus voriconazole monotherapy for primary treatment of invasive aspergillosis. 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID); London, UK; March 31–April 3, 2012. Abstract LB2812.
175. Pfaller MA, Diekema DJ, Gibbs DL, ,Newell VA, Ellis D, Tullio V, Rodloff A, Fu W, Ling TA; Global Antifungal Surveillance Group. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diff usion. J Clin Microbiol 2010; 48: 1366–1377.
176. Maertens J, Glasmacher A, Herbrecht R, Thiebaut A, Cordonnier C, Segal BH, Killar J, Taylor A, Kartsonis N, Patterson TF, Aoun M, Caillot D, Sable C; Caspofungin Combination Therapy Study Group. Multicenter, noncomparative study of caspofungin in combination with other antifungals as salvage therapy in adults with invasive aspergillosis. Cancer 2006; 107: 2888–2897.
177. Glasmacher A, Hahn C, Leutner C, Molitor E, Wardelmann E, Losem C, Sauerbruch T, Marklein G, Schmidt-Wolf IG. Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole. Mycoses. 1999; 42: 443-451.
178. Trifilio S, Singhal S, Williams S, Frankfurt O, Gordon L, Evens A, Winter J, Tallman M, Pi J, Mehta J . Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant. 2007; 40: 451-456.
179. Walsh TJ, Raad I, Patterson TF, Chandrasekar P, Donowitz GR, Graybill R, Greene RE, Hachem R, Hadley S, Herbrecht R, Langston A, Louie A, Ribaud P, Segal BH, Stevens DA, van Burik JA, White CS, Corcoran G, Gogate J, Krishna G, Pedicone L, Hardalo C, Perfect JR. Treatment of invasive aspergillosis with posaconazole in patients who are refractory to or intolerant of conventional therapy: An externally controlled trial. Clin Infect Dis. 2007; 44: 2-12.
180. Denning DW, Marr KA, Lau WM, Facklam DP, Ratanatharathorn V, Becker C, Ullmann AJ, Seibel NL, Flynn PM, van Burik JA, Buell DN, Patterson TF. Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis. J Infect 2006; 53:337–349.
181. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, Kern WV, Marr KA, Ribaud P, Lortholary O, Sylvester R, Rubin RH, Wingard JR, Stark P, Durand C, Caillot D, Thiel E, Chandrasekar PH, Hodges MR, Schlamm HT, Troke PF, de Pauw B; Invasive Fungal Infections Group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin b for primary therapy of invasive aspergillosis. N Engl J Med. 2002; 347: 408-415.
182. Walsh TJ, Lutsar I, Driscoll T, Dupont B, Roden M, Ghahramani P, Hodges M, Groll AH, Perfect JR. Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children. Pediatr Infect Dis J. 2002; 21: 240-248.
183. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004; 39: 1563-1571.
184. Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, Heussel CP, Lortholary O, Rieger C, Boehme A, Aoun M, Horst HA, Thiebaut A, Ruhnke M, Reichert D, Vianelli N, Krause SW, Olavarria E, Herbrecht R; AmBiLoad Trial Study Group. Liposomal amphotericin b as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (ambiload trial). Clin Infect Dis. 2007; 44: 1289-1297.
185. Raad, II, Hanna HA, Boktour M, Jiang Y, Torres HA, Afif C, Kontoyiannis DP, Hachem RY . Novel antifungal agents as salvage therapy for invasive aspergillosis in patients with hematologic malignancies: Posaconazole compared with high-dose lipid formulations of amphotericin b alone or in combination with caspofungin. Leukemia. 2008; 22: 496-503.
186. Cornely OA, Maertens J, Bresnik M, Ullmann AJ, Ebrahimi R, Herbrecht R. Treatment outcome of invasive mould disease after sequential exposure to azoles and liposomal amphotericin b. J Antimicrob Chemother. 2010; 65: 114-117.
187. Winston DJ, Bartoni K, Territo MC, Schiller GJ. Efficacy, safety, and breakthrough infections associated with standard long-term posaconazole antifungal prophylaxis in allogeneic stem cell transplantation recipients. Biol Blood Marrow Transplant. 2011; 17: 507-515.
188. De la Serna J, Jarque I, Lopez-Jimenez J, Vallejo C. Treatment of invasive fungal infections in high risk hematological patients. The outcome with liposomal amphotericin b is not negatively affected by prior administration of mold-active azoles. Rev Esp Quimioter. 2013; 26: 64-69.
189. Auberger J, Lass-Florl C, Aigner M, Clausen J, Gastl G, Nachbaur D. Invasive fungal breakthrough infections, fungal colonization and emergence of resistant strains in high-risk patients receiving antifungal prophylaxis with posaconazole: Real-life data from a single-centre institutional retrospective observational study. J Antimicrob Chemother. 2012; 67: 2268-2273.
190. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, Sable CA, Kartsonis NA, Ngai A, Taylor A, Patterson TF, Denning DW, Walsh TJ; Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39:1563–1571.
191. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, de la Torre-Cisneros J, Just-Nübling G, Schlamm HT, Lutsar I, Espinel-Ingroff A, Johnson E. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis 2003; 36:1122–31.
192. Ng TT, Denning DW. Liposomal amphotericin B (AmBisome) therapy in invasive fungal infections. Evaluation of United Kingdom compassionate use data. Arch Intern Med 1995; 155:1093–1098.
193. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, Silber JL, DiNubile MJ, Reboli A, Bow E, Lister J, Anaissie EJ. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383–1396.
194. Prentice HG, Hann IM, Herbrecht R, ,Aoun M, Kvaloy S, Catovsky D, Pinkerton CR, Schey SA, Jacobs F, Oakhill A, Stevens RF, Darbyshire PJ, Gibson BE. A randomized comparison of liposomal versus conventional amphotericin b for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol. 1997; 98: 711-718.
195. Maertens JA, Madero L, Reilly AF, Lehrnbecher T, Groll AH, Jafri HS, Green M, Nania JJ, Bourque MR, Wise BA, Strohmaier KM, Taylor AF, Kartsonis NA, Chow JW, Arndt CA, DePauw BE, Walsh TJ; Caspofungin Pediatric Study Group. A randomized, double-blind, multicenter study of caspofungin versus liposomal amphotericin b for empiric antifungal therapy in pediatric patients with persistent fever and neutropenia. Pediatr Infect Dis J. 2010; 29: 415-420.
196. Caselli D, Paolicchi O. Empiric antibiotic therapy in a child with cancer and suspected septicemia. Pediatr Rep. 2012; 4: e2.
197. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, Dhédin N, Isnard F, Ades L, Kuhnowski F, Foulet F, Kuentz M, Maison P, Bretagne S, Schwarzinger M. .Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial. Clin Infect Dis. 2009; 48: 1042-1051.
198. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, Capria S, Minotti C, Cartoni C, Brocchieri S, Guerrisi V, Meloni G, Foà R, Martino P. Clinically driven diagnostic antifungal approach in neutropenic patients: A prospective feasibility study. J Clin Oncol. 2010; 28: 667-674.
199. Tan BH, Low JG, Chlebicka NL, Kurup A, Cheah FK, Lin RT, Goh YT, Wong GC. Galactomannan-guided preemptive vs. Empirical antifungals in the persistently febrile neutropenic patient: A prospective randomized study. Int J Infect Dis. 2011; 15: e350-356.
200. Castagnola E, Bagnasco F, Amoroso L, Caviglia I, Caruso S, Faraci M, Calvillo M, Moroni C, Bandettini R, Cangemi G, Magnano GM, Buffa P, Moscatelli A, Haupt R. Role of management strategies in reducing mortality from invasive fungal disease in children with cancer or receiving hemopoietic stem cell transplant: A single center 30-year experience. Pediatr Infect Dis J. 2014; 33: 233-237.
201. Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR; Infectious Diseases Society of America. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis 2011; 52: 427–431.